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Introduction: Medicinal herbs have several components with different pharmacological 
effects. It has been described that Melissa officinalis is able to improve memory in different 
models of learning. Nevertheless, its influence has not been studied in animal models of AD. 
Here, we studied the potential therapeutic effect of M. officinalis in intracerebroventricular 
(i.c.v) amyloid-β (Aβ) model of Alzheimer’s disease (AD). 
Methods: Male Wistar rats weighing 260-330 g received the hydro-alcoholic extract of M. 
officinalis (50, 100, 200, 400 mg/kg; P.O), chronically for 30 consecutive days. The control group 
received solvent of the drug. Memory retrieval was assessed, using the passive avoidance task. 
Three groups of the rats received Aβ (1-42; 10 μg/rat bilaterally; i.c.v). One group received 
DMSO 1% (2 μL/rat; i.c.v). Twenty days later memory retrieval was assessed. The Aβ-treated 
rats, received M. officinalis (50, 100 mg/kg; P.O) or saline (1 mL/kg; P.O), chronically for 30 
consecutive days. The DMSO 1%-treated rats received saline (1 mL/kg; P.O). 
Results: The hydro-alcoholic extract of M. officinalis (50, 100, 200, 400 mg/kg; P.O) did not have 
a significant effect on step-through latency (STL). Aβ impaired memory retrieval by decreasing 
STL and increasing the time spent in the dark compartment (TDC). M. officinalis (50, 100 
mg/kg; P.O) improved memory retrieval in AD rats by increasing STL and decreasing TDC, 
significantly. 
Conclusion: The outcomes of the study show that M. officinalis has a therapeutic effect in the 
Aβ model of AD. It seems that the extracts of M. officinalis can be suggested as a powerful 
therapeutic herb for AD patients.
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A B S T R A C T
Introduction
Alzheimer’s disease (AD) is an enduring, progressive and 
irreversible neurodegenerative syndrome and is the central 
cause of dementia in later life. Two neuropathological 
features of AD are neuritic plaques and neuroﬁbrillary 
tangles which are respectively related to the buildup of the 
amyloid-beta peptide (Aβ) in the brain, and to cytoskeletal 
alterations that appear due to the hyper-phosphorylation 
of tau protein in neurons. Aβ-peptide has a crucial impact 
to the pathogenesis of AD (1). Based on the amyloid theory, 
accretion of Aβ in the brain is the major impact driving 
AD pathogenesis. Other aspect of the disease progression, 
including creation of neurofibrillary tangles comprising 
tau protein, is suggested to result from an inequality 
between Aβ production and Aβ clearance. Aβ deposit 
leads to oxidative stress, mitochondrial abnormalities and 
depletion of cellular ATP, elevated intracellular calcium and 
excitotoxicity and induction of inflammatory responses. 
All these mechanisms result in synaptic dysfunction and 
cause neuronal loss through activation of apoptotic and 
necrotic cell death pathways (2). Intracerebroventricular 
(i.c.v) injection of Aβ molecules leads to the buildup 
of Aβ plaques in the brain tissue, oxidative stress and 
neurotoxicity, which results in impairment of memory 
characteristic of the AD (3). It has been commonly used 
as an animal model of AD (4-6). The step-through passive 
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avoidance paradigm is a learning task that has been widely 
utilized to assess the involvement of various treatments in 
learning and memory (7). 
Treatment of AD is a great clinical challenge. Despite all 
the advances in this field, there is not a complete curative 
strategy for patients with AD. Due to the multifaceted 
pathology of AD, novel therapeutic strategies aim to 
stop disease progress through different pathways (8). 
Medicinal herbs have numerous constituents with 
diverse pharmacological properties and may be effective 
in complex diseases like AD. Hence, several studies 
have been considered to evaluated therapeutic effects of 
herbal medicines in AD therapy (9). Melissa officinalis 
is a medicinal herb from Lamiaceae family. It has been 
consumed as a medicinal plant for more than 2000 years 
(10). It has putative anti-inflammatory, antioxidant, 
neuro-protective, binding capacity to cholinergic 
receptors and anti-cholinesterase activity. It is suggested 
to be effective in the hindrance of various neurological 
diseases accompanied with oxidative stress (11) and 
has the potential to provide a natural treatment for AD 
(12). Acute injection of M. officinalis modulated mood 
and memory performance in healthy young individuals. 
Meanwhile, no side effects or toxicities have been 
described with its use (13). 
Melissa officinalis is traditionally used to improve 
memory, however, there are not any reports assessing its 
effect in animal models of AD. Due to the central role of 
Aβ in AD pathogenesis, here we investigated the potential 
therapeutic activity of chronic injections of the hydro-
alcoholic extract of M. officinalis in the Aβ rat model of 
AD. 
Materials and Methods
Chemicals
Ketamine and xylazine were purchased from Alfasan (the 
Netherland). Aβ (1-42) was purchased from Sigma (USA) 
and dissolved in DMSO 1%. Dried leaves of M. officinalis 
were a gift from Iraninoosh Company which gathered it 
from Kamfiruz, Fars province, Iran in 2014.
Animals
Adult male Wistar rats (260–330 g) were obtained from 
the breeding colony of Department of Biology, University 
of Isfahan. Rats were kept four per cage in a temperature 
(24±1°C) well-ordered room that was upheld on a 12:12 
light cycle (light on at 07:00 am). The rats had unrestricted 
access to food and water. After the surgery for cannula 
embedding, the rats were housed alone in standard 
cages. All experiments were performed in agreement 
with the guide for the care and use of laboratory animals 
(USA National Institute of Health publication No. 80-23, 
revised 1996) and were approved by the graduate studies 
committee of the Department of Biology, University of 
Isfahan.
Preparation of the hydro-alcoholic extract of Melissa 
officinalis
One hundred grams of dried leaves of M. officinalis 
were pulverized, using a mixing instrument (Molineux, 
France), then were soaked in 400 mL of 96% ethanol, 
while mixing in a stirrer. The solution was filtered and put 
in a dark glass after 24 hours. The remaining crude was 
again soaked in 400 mL of 70% ethanol for 24 hours. The 
solution was again filtered and mixed with the previous 
solution. The extract was then concentrated in a rotary 
evaporator and dried in an oven in 40°C for 72 hours. 
The resulting extract was dissolved in saline to a final 
concentration of 100 mg/mL. The animals received the 
extract through gavage.
Surgical procedures 
Rats were anesthetized with a combination of ketamine 
(100 mg/kg, i.p) and xylazine (10 mg/kg, i.p) and were 
bilaterally embedded with guide cannula (22-gauge) 
targeted at site 1 mm dorsal to the lateral ventricles 
(anterior-posterior: −0.9 mm from bregma, midline: ±1.4 
mm from midline, and dorsal-ventral: −2.5 mm from 
dura) based on the atlas of Paxinos and Watson (14). A 
screw was implanted into the skull and cannulas were 
ﬁxed to it with dental cement. The cannulas were locked 
with stainless steel stylets smeared with mineral oil to 
avoid clogging with blood.
Microinjection procedure
Intracerebroventricular injections were done via guide 
cannula with needles (27-gauge) that were joined by 
polyethylene tubing (PE20, Stoelting) to a 2 μL Hamilton 
micro syringe. The injections (2 μL total volume) were 
conveyed over 4 minutes bilaterally (1 μL each side), and 
the injection needles (extending 1mm from the end of the 
guide cannula) were left in place an extra minute, then 
they were slowly withdrawn.
Passive avoidance task
The step-through passive avoidance task was executed 
to evaluate memory performance, as formerly described 
(15). Briefly, each rat was positioned in the white 
compartment of the PAT apparatus facing the sliding door. 
After 5 seconds the door was elevated. When the animal 
walked into the dark compartment with all four paws, the 
door was closed and the rat stayed there for 20 seconds. 
Then the animal was removed to be sited in a temporary 
cage. 30 minutes later, the rat was again positioned in 
the white compartment for 5 seconds, then the door was 
elevated to let the animal enter the dark compartment 
and after entrance, the door was shut, but this time a 
controlled electrical shock of 0.3 mA lasting for 1 second 
was delivered. After 20 seconds, the rat was sited into 
the temporary cage. Two minutes later, the same testing 
process was reiterated. When the rat stayed in the white 
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compartment for a 2-minute times period, the training 
was ended. On the second day, a retrieval test was done 
to assess long-term memory. Each animal was positioned 
in the white start compartment for 20 seconds, then the 
door was elevated and the step-through latency (STL) 
and the time spent in the dark compartment (TDC), were 
recorded, up to 600 seconds.
Experiment 1
Eight rats were used in each experimental group. In this 
experiment, the effect of chronic injection of different 
doses of the hydro-alcoholic extract of M. officinalis was 
assessed on memory performance. Five groups of animals 
received the hydro-alcoholic extract of M. officinalis (50, 
100, 200 and 400 mg/kg; P.O) or Saline (1 mL/kg; P.O) for 
30 consecutive days. Memory retrieval was assessed using 
a passive avoidance paradigm.
Experiment 2
In this experiment, the effect of i.c.v administration of Aβ 
was assessed on memory performance in rats. One group 
of animals received Aβ (10 μg/rat), bilaterally. The dose of 
Aβ was selected according to previous reports (16). The 
control group received DMSO 1%. Twenty days following 
the injection, memory retrieval was evaluated.
Experiment 3
In this experiment, the effect of the hydro-alcoholic extract 
of M. officinalis was assessed on memory performance 
in Aβ-treated rats. The animals were allocated into four 
groups. Group 1 received DMSO 1% (2 μL/rat; i.c.v). 
Groups 2, 3 and 4 received Aβ (10 μg/rat; i.c.v), bilaterally. 
Twenty days later, memory performance was assessed. 
Afterwards, groups 1 and 2 received saline (1 mL/kg; 
P.O) for 30 consecutive days. Groups 3 and 4 received the 
hydro-alcoholic extract of M. officinalis (50 or 100 mg/
kg; P.O), respectively for 30 consecutive days. Memory 
performance was assessed again after completion of the 
treatment regimen (Figure 1).
Statistical analysis
One-way analysis of variance (ANOVA) followed by 
Tukey-Kramer multiple comparison post-hoc test, un-
paired or paired t tests were performed using GraphPad 
Prism version 5.04 for Windows. In all experiments, 
differences were considered statistically signiﬁcant at 
the level of P ˂  0.05. The data are presented as mean ± 
standard error of the mean (SEM).
Results
Veriﬁcation of cannulas placements 
At the end of the experiments, each animal was euthanized 
with an overdose of chloroform. The brain was removed 
and ﬁxed in a 10% formalin solution and sectioned 5 days 
later. Sections were inspected to determine the site of the 
cannulas targeted for the lateral ventricles. The cannula 
placements were confirmed using the atlas of Paxinos and 
Watson (14). Data from the animals with the injection 
sites placed outside the lateral ventricles were not used for 
the analysis.
The effect of the hydro-alcoholic extract of Melissa 
officinalis on memory retrieval
In the passive avoidance task, the decrease in STL and 
the increase in TDC indicate loss of fear memory. One-
way ANOVA showed that the hydro-alcoholic extract of 
M. officinalis (50, 100, 200 and 400 mg/kg) did not have a 
significant effect on STL (P > 0.05; Figure 2). 
The effect of Aβ on memory retrieval
Intracerebroventricular injection of Aβ impaired 
memory retrieval by decreasing STL and increasing TDC, 
significantly compared with the control group (Figure 3; 
P < 0.05).
The effect of the hydro-alcoholic extract of Melissa 
officinalis on memory retrieval in rats treated with Aβ
One-way ANOVA indicated a significant main effect 
of STL following chronic i.c.v injections of the hydro-
alcoholic extract of M. officinalis in the Aβ-treated rats 
(F [3, 31] = 5.21; P = 0.005). Post hoc comparison showed 
that M. officinalis (50 and 100 mg/kg; P.O) signiﬁcantly 
increased STL as compared to the group received Aβ-
saline (Table 1; P < 0.05). Data analysis of this experiment 
Figure 1. Diagram illustrating experimental design.
Figure 2. The effect of the hydro-alcoholic extract of Melissa officinalis 
on step-through latency (STL). Data are shown as means ±SEM and 
were analyzed by ANOVA.
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also revealed main effect of TDC (F [3, 31] = 4.30; P = 0.01). 
Post hoc comparisons showed that M. officinalis (50 mg/
kg; P.O), signiﬁcantly decreased TDC in the Aβ-treated 
rats as compared to the group received Aβ-saline (Table 
2; P < 0.05). Post-hoc comparisons also revealed that M. 
officinalis (100 mg/kg; P.O), significantly reduced TDC in 
the Aβ-treated rats as compared to the group received Aβ-
saline (Table 2; P < 0.01).
Discussion
The main finding of the current study was that chronic 
consumption of the hydro-alcoholic extract of M. officinalis 
has a therapeutic effect in rats with AD induced by i.c.v 
(A)
(B)
Figure 3. The effect of bilateral injection of Aβ (10 μg/rat; i.c.v) on (A) 
step-through latency (STL) and (B) TDC (the time spent in the dark 
compartment). Data are shown as means ± SEM and were analyzed 
by un-paired t test. *P < 0.05.
Table 1. The effect of Melissa officinalis  on step-through latency (STL) in Aβ-treated rats
21 days after surgery 52 days after surgery
Aβ treatment of rats (single injection) M. officinalis treatment of rats (30 days) treated with Aβ 
Group 1 DMSO 1% (2 μL/rat; i.c.v) Saline (1 mL/kg; P.O)
274±79.00 400±97.00
Group 2 Aβ (10 μg/rat; i.c.v) Saline (1 mL/kg; P.O)
51.28±15.00 66.50±20
Group 3 Aβ (10 μg/rat; i.c.v) M. officinalis (50 mg/kg; P.O)
76.33±29.41 365.70±93.23*
Group 4 Aβ (10 μg/rat; i.c.v) M. officinalis (100 mg/kg; P.O)
60.63±20.29 309.00±63.97*
Data are shown as means ± SEM and were analyzed by paired t test. * P<0.05.
injections of Aβ. In AD there is a gradual loss of cholinergic 
neurons in basal forebrain which has been suggested to 
cause the cognitive deficits observed in patients with AD 
(17). Drugs used for AD treatment are acetylcholinesterase 
inhibitors, which can improve cognitive impairment but 
cannot prevent disease progression (18). M. officinalis has 
a variety of components, of which the most important 
are phenolic compounds, rosmarinic acid, caffeic acid, 
cholinergic acid, metrilic acid; flavonoids such as luteolin, 
apigenin and monoterpene derivatives; the sesquiterpenes 
including beta-caryophyllene and germacrene; triterpenes 
such as oleanolic and ursolic acid; volatile oil, and tannins 
(19). Some of these compounds have binding capacity 
to nicotinic and muscarinic acetylcholine receptors and 
also inhibit the effects of acetylcholinesterase enzyme 
(20-22). Thus, by regulating the cholinergic system it 
might be helpful in Alzheimer’s treatment and adjusting 
mood and cognitive processes. In M. officinalis extract the 
affinity for acetylcholine nicotinic receptor is more than 
muscarinic receptor (23). It was reported that nicotinic 
receptor stimulation, may be able to protect neurons from 
degeneration induced by Aβ and may have effects that 
stand the progress of AD.
Oxidative stress is the mechanism that was assumed for Aβ 
toxicity and Alzheimer’s etiology (24). Aβ is accumulated 
and creates more free radicals in the presence of free 
radicals. In this regard, M. officinalis total extract could 
attenuate the Aβ-induced toxicity and oxidative stress 
(22). Direct free radical scavenging activity has been 
reported for M. officinalis. The total extract could defend 
PC12 cells against hydrogen peroxide-induced cell death 
and oxidative stress (25). Antioxidants can ameliorate 
disease progression (26), so it is supposed that antioxidant 
activity of M. officinalis may have contributed to neuro-
protective effect against Aβ toxicity.
Different biological activities have been designated for the 
major polyphenol component of M. officinalis, rosmarinic 
acid, including anti-oxidative and anti-inflammatory 
activities (27). Rosmarinic acid could protect against Aβ-
induced memory impairment in mice, due to the direct 
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peroxynitrite scavenging activity (28). Rosmarinic acid 
protected mice against impairment of memory induced 
by i.c.v injection of Aβ (28). It could also lower Aβ 
depositions in ovariectomized rats and improve short-
term spatial memory (29). 
The caffeic acid and the ursolic acid found in M. officinalis 
were reported to have neuro-protective effects. Ursolic 
acid is a triterpenoid with hydroxyl radical scavenging 
activity and it augmented the activities of antioxidant 
enzymes like superoxide dismutase, catalase and 
glutathione peroxidase (30). Caffeic acid improved Aβ-
induced cognitive damage through inhibition of lipid 
peroxidation and NO production (31). Caffeic acid also 
exerted neuro-protective and anti-dementia effects by 
preventing the loss of neural cells and synapses in mice 
ischemic brain injury (32).
Another active component of M. officinalis, luteolin could 
improve Aβ-induced memory deficiency and increased 
the activity of choline acetyl transferase, superoxide 
dismutase and glutathione peroxidase in hippocampal 
tissue. Luteolin also inverted the augmented activity of 
acetylcholine esterase. In hippocampi homogenate, the 
amount of acetylcholine augmented, but malondialdehyde 
reduced. Moreover, luteolin could raise Bcl-2/Bax ratio. 
Luteolin could protect AD rats against Aβ-induced 
memory deficiency through regulating the cholinergic 
system and inhibiting oxidative damages (33). Luteolin 
also improved learning and memory in Aβ-induced 
cognition damage in rats by activating the anti-oxidation 
system (34). Luteolin reduced the impairment of passive 
avoidance memory induced by scopolamine by increasing 
the activities of the brain muscarinic and nicotinic 
receptors (35).
Apigenin, another component of M. officinalis, attenuated 
cognitive deterioration in diabetic rats via suppressing 
oxidative stress, nitric oxide and apoptotic cascades 
synthase pathway (36). Oral administration of apigenin 
for three month rescued learning deficits and improved 
memory retention in APP/PS1 double transgenic 
AD mice. Apigenin also affected APP processing and 
prevented Aβ load, the relief of Aβ deposition, and the 
decrease of insoluble Aβ levels. Moreover, apigenin 
showed superoxide anion scavenging effects and enhanced 
antioxidative enzyme activity of superoxide dismutase 
and glutathione peroxidase (37).
Oral administration of β-Caryophyllene, another 
compound found in M. officinalis prohibited cognitive 
deficiency in APP/PS1 mice, and this positive cognitive 
effect was concomitant with reduced β-amyloid load 
in the hippocampus and the cerebral cortex. Moreover, 
β-caryophyllene reduced astrogliosis and microglial 
activation and the levels of cyclooxygenase-2 protein 
and the mRNA levels of the tumor necrosis factor-α and 
interleukin-1β in the cerebral cortex (38). 
Due to the above mentioned beneficial effects of the 
components of M. officinalis on improvement of memory, 
oxidative stress, inflammatory conditions, neuro-
protection, anti-cholinesterase activities and Aβ clearance, 
it seems that M. officinalis can be suggested as a powerful 
therapeutic herb for AD patients.
In accordance with our results, M. officinalis enhanced 
spatial memory in the Morris water maze in streptozotocin-
induced memory impairment in rats and reduced amyloid 
plaques (39). Also, in a clinical trial it could improve 
disease signs in patients with mild to moderate AD (40). 
Based on the outcomes of the current study and these 
studies, it appears that M. officinalis have components 
with a great potential to treat AD.
Conclusion
As a conclusion, the outcomes of the current study 
indicated potential therapeutic effects of the hydro-
alcoholic extract of M. officinalis in the i.c.v Aβ model 
of AD. The anti-inflammatory, anti-oxidant, neuro-
protective and anti-cholinesterase activities of the extract 
are proposed to be involved in the observed results. 
Further studies are requisite to clarify the mechanisms of 
this activity and identify the responsible components of 
the extract.
Table 2. The effect of Melissa officinalis on TDC (the time spent in the dark compartment) in Aβ-treated rats
21 days after surgery 52 days after surgery
Aβ treatment of rats (single injection) M. officinalis treatment of rats (30 days) treated with Aβ 
Group 1 DMSO 1% (2 μL/rat; i.c.v) Saline (1 mL/kg; P.O)
86.43±25.10 95±15.00
Group 2 Aβ (10 μg/rat; i.c.v) Saline (1 mL/kg; P.O)
231.10±40.00 250±49.00
Group 3 Aβ (10 μg/rat; i.c.v) M. officinalis (50 mg/kg; P.O)
228.40±38.16 79.56±40.90*
Group 4 Aβ (10 μg/rat; i.c.v) M. officinalis (100 mg/kg; P.O)
291.70±59.91 8.71± 2.63**
Data are shown as means ± SEM and were analyzed by paired t test. * P<0.05.
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